Morepen Laboratories Limited Stock Price Today (NSE: MOREPENLAB)
Fundamental Score
Morepen Laboratories Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Morepen Laboratories Limited share price today is ₹113.35, down 5.00% on NSE/BSE as of 30 October 2026. Morepen Laboratories Limited (MOREPENLAB) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹6.21K (Cr). The 52-week high for MOREPENLAB share price is ₹150.70 and the 52-week low is ₹33.05. At a P/E ratio of 44.28x, MOREPENLAB is currently trading above its industry average P/E of 34.89x. 0
Morepen Laboratories Limited Share Price Chart — NSE/BSE Historical Performance
Morepen Laboratories Limited share price chart: 7.97% return over the past month. 52-week high ₹150.70, 52-week low ₹33.05.
Morepen Laboratories Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹113.35 | ₹122.23 | ₹113.35 | ₹113.35 | 88.58L (Cr) | |
| ₹119.31 | ₹119.31 | ₹119.31 | ₹119.31 | 9.00L (Cr) | |
| ₹128.00 | ₹130.55 | ₹125.58 | ₹125.58 | 51.16L (Cr) | |
| ₹129.00 | ₹132.31 | ₹127.55 | ₹132.18 | 76.16L (Cr) | |
| ₹123.45 | ₹128.00 | ₹119.01 | ₹126.01 | 40.31L (Cr) | |
| ₹115.25 | ₹123.55 | ₹113.00 | ₹123.54 | 50.64L (Cr) | |
| ₹111.60 | ₹121.19 | ₹110.20 | ₹117.67 | 39.09L (Cr) | |
| ₹119.99 | ₹123.50 | ₹115.42 | ₹115.42 | 47.84L (Cr) | |
| ₹125.50 | ₹125.75 | ₹117.90 | ₹121.49 | 41.58L (Cr) | |
| ₹124.20 | ₹127.88 | ₹121.90 | ₹123.87 | 26.66L (Cr) |
Morepen Laboratories Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹125.90 | ₹150.70 | ₹110.20 | ₹113.35 | -9.97% | |
| ₹107.16 | ₹128.10 | ₹97.04 | ₹125.99 | +17.57% | |
| ₹58.00 | ₹110.38 | ₹55.91 | ₹107.16 | +84.76% | |
| ₹59.79 | ₹64.58 | ₹51.38 | ₹57.04 | -4.60% | |
| ₹43.77 | ₹60.50 | ₹42.50 | ₹59.12 | +35.07% | |
| ₹41.80 | ₹47.00 | ₹39.69 | ₹43.24 | +3.44% | |
| ₹34.56 | ₹44.18 | ₹34.56 | ₹41.36 | +19.68% | |
| ₹41.10 | ₹43.25 | ₹33.05 | ₹33.68 | -18.05% | |
| ₹36.63 | ₹48.84 | ₹34.83 | ₹43.67 | +19.22% | |
| ₹41.07 | ₹42.44 | ₹33.50 | ₹36.31 | -11.59% | |
| ₹43.60 | ₹44.40 | ₹38.42 | ₹41.07 | -5.80% | |
| ₹47.60 | ₹48.48 | ₹42.49 | ₹43.40 | -8.82% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Morepen Laboratories Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Morepen Laboratories Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of MOREPENLAB across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Strong Revenue Growth (34.07%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.16)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (8.31x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 2.37)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Below-Average Return on Equity (0.00%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Premium Valuation Risk (P/E: 44.28x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-22.54%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Weak Earnings Growth (-4.34% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-5.17% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Negative Free Cash Flow (₹-507.77 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 2.74%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Morepen Laboratories Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Morepen Laboratories Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Morepen Laboratories LimitedMorepen Laborat...Selected✓ MOREPENLAB • 500288 | 26/100 | ₹113.35₹113 | ₹6210.68₹6210.68 | 44.28Average 44.3 Average | 0.00%Poor 0.00% Poor | 10.01%Average 10.01% Average | 0.16Excellent 0.2 Excellent | -5.17%Poor -5.17% Poor | 8.73%Good 8.73% Good | 0.33% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 72.9/100 | ₹1758.80₹1759 | ₹421988.88₹421988.88 | 34.90Average 34.9 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 67.2/100 | ₹9144.50₹9145 | ₹242329.25₹242329.25 | 82.97Average 83.0 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 54.8/100 | ₹4558.90₹4559 | ₹154300.53₹154300.53 | 72.83Average 72.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 71.6/100 | ₹1123.00₹1123 | ₹112075.40₹112075.40 | 25.03Average 25.0 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 53.5/100 | ₹2060.10₹2060 | ₹111296.90₹111296.90 | 101.68Average 101.7 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 35.2/100 | ₹1325.10₹1325 | ₹107048.20₹107048.20 | 31.75Average 31.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 36.5/100 | ₹1233.00₹1233 | ₹102955.50₹102955.50 | 31.87Average 31.9 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1666.90₹1667 | ₹95913.43₹95913.43 | 26.05Average 26.0 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 59.7/100 | ₹2275.50₹2276 | ₹93978.15₹93978.15 | 45.98Average 46.0 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 77.1/100 | ₹1961.60₹1962 | ₹89694.16₹89694.16 | 16.21Average 16.2 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price421988.88 Cr
- Divi's Laboratories Limited share price242329.25 Cr
- Torrent Pharmaceuticals Limited share price154300.53 Cr
- Zydus Lifesciences Limited share price112075.40 Cr
- Laurus Labs Limited share price111296.90 Cr
Morepen Laboratories Limited PE Ratio History
Historical price-to-earnings ratio for MOREPENLAB — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹2.20 | ₹41.07 | 18.7x |
| FY 2024 | ₹1.88 | ₹78.16 | 41.6x |
| FY 2023 | ₹0.77 | ₹48.55 | 63.1x |
| FY 2022 | ₹1.96 | ₹37.85 | 19.3x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Morepen Laboratories Limited Quarterly Performance
Latest quarterly metrics for MOREPENLAB — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
34.07%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-22.54%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
8.73%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-5.17%
Compounded annual net profit growth over 5 years
Morepen Laboratories Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for MOREPENLAB — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Morepen Laboratories Limited Financial Statements
Annual income statement, balance sheet and cash flow for Morepen Laboratories Limited (MOREPENLAB) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Morepen Laboratories Limited
About MOREPENLAB (Morepen Laboratories Limited)
Morepen Laboratories Ltd is a versatile pharmaceutical organization deeply rooted in the global healthcare landscape. With a firm commitment to innovation and quality, the company ...navigates a diverse portfolio encompassing the development, production, and distribution of a wide array of pharmaceutical products. From foundational Active Pharmaceutical Ingredients (APIs) that serve as building blocks for life-saving medications, to meticulously crafted branded and generic formulations, Morepen caters to varied therapeutic needs. Furthermore, their venture into home health products empowers individuals to proactively manage their well-being, reflecting a holistic approach to healthcare. This integrated structure allows Morepen to maintain a robust presence across multiple market segments, consistently striving to meet the evolving demands of patients and healthcare professionals worldwide. The company's API segment fuels the creation of essential drugs across a spectrum of therapeutic areas. Morepen produces the foundational components needed for medications addressing conditions such as allergies, respiratory ailments, high cholesterol, hypertension, diabetes, blood clotting disorders, digestive issues, and mental health disorders. Beyond APIs, Morepen formulates and markets a range of branded and generic medications, ensuring accessibility to vital treatments. This dual approach allows the company to cater to both large pharmaceutical manufacturers and individual consumers, expanding its reach and impact on global health. By consistently upholding stringent quality standards and investing in research and development, Morepen solidifies its position as a reliable supplier of essential pharmaceutical products. Morepen Laboratories extends its reach beyond prescription drugs by offering a suite of consumer-focused home health products. Recognizing the growing importance of self-monitoring and preventative care, they provide devices that allow individuals to actively manage their health from the comfort of their homes. This includes products designed to improve air quality, along with instruments for monitoring vital signs such as blood pressure and blood glucose levels. These products empower individuals to take a proactive role in their healthcare journey, fostering a sense of control and contributing to better overall health outcomes. By diversifying into the home health sector, Morepen demonstrates its commitment to providing comprehensive healthcare solutions that address a wide range of needs.
Company Details
Key Leadership
MOREPENLAB Share Price: Frequently Asked Questions
What is the current share price of Morepen Laboratories Limited?
Morepen Laboratories Limited (MOREPENLAB) trades at ₹113.35 on NSE and BSE. Market cap ₹6.21K (Cr). Educational data only.
What is the P/E ratio of Morepen Laboratories Limited?
Morepen Laboratories Limited has a P/E of 44.28x vs industry average 34.89x.
What is the Bull Run score for Morepen Laboratories Limited?
Morepen Laboratories Limited has a Bull Run score of 26/100 based on 25+ financial parameters.
Does Morepen Laboratories Limited pay dividends?
Morepen Laboratories Limited has a dividend yield of 0.33%. Past dividends don't guarantee future payments.
What is the ROE of Morepen Laboratories Limited?
Morepen Laboratories Limited has ROE of 0.00%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Morepen Laboratories Limited?
Morepen Laboratories Limited has debt-to-equity of 0.16.
Is Morepen Laboratories Limited a good investment?
Bull Run gives Morepen Laboratories Limited a score of 26/100. This is not investment advice — consult a SEBI-registered advisor.